People often use “food noise” to describe recurring thoughts about eating, cravings or the mental effort of deciding whether to eat. Researchers usually measure more specific experiences, such as hunger, food preoccupation, cravings and control of eating.[1][2]

Semaglutide and tirzepatide act on receptors involved in appetite regulation and can reduce calorie intake. That provides a biological explanation for why eating may feel different during treatment.[3][4]

What have studies found?

A small randomized crossover study of semaglutide in adults with obesity found less hunger and fewer cravings, better control of eating and lower measured food intake compared with placebo. Nausea ratings were similar between treatments, so the appetite findings were not simply a report that participants felt too sick to eat.[1]

A later 60-week randomized study in 120 adults measured both laboratory food intake and subjective appetite. Semaglutide reduced food intake compared with placebo at weeks 20, 40 and 60. Some reported appetite benefits, including less food preoccupation, were clearer early in treatment and were not significantly different between groups at the later assessments.[2]

Those findings explain an important distinction: how hungry someone feels and how much they eat can change differently over time.[2]

Hunger can still be present

The trials assessed average changes in particular measures. They did not establish complete absence of hunger or food thoughts as a requirement for treatment benefit.[1][2]

The useful comparison is with your own eating experience over time.

What is worth noticing?

A useful description names the change: fewer cravings, less preoccupation between meals, different portions, or more comfortable control over eating. It also separates those experiences from nausea or an inability to eat enough, which belong in a side-effect review.[1][3][4]

Follow-up can consider both the changes you value and any difficulty eating enough.[2][3][4]